When Is It Safe to Switch to Amjevita?
Switching from Humira to a biosimilar like Amjevita, made by Eli Lilly, requires careful consideration and consultation with your doctor. According to the Amjevita Prescribing Information, Amjevita is approved for the treatment of certain autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Why Switch at All?
You might want to switch to Amjevita if you're eligible for a savings program or if you've been experiencing difficulties with Humira's efficacy or affordability. However, it's essential to discuss the risks and benefits with your doctor, as studies on biosimilar efficacy can provide insights, but individual reactions may vary.
What You Should Discuss with Your Doctor
Before switching to Amjevita, you should consult your doctor to determine if this alternative is suitable for you. Some factors to discuss include:
- Biosimilar efficacy and safety: Your doctor can assess the likelihood of a smooth transition and identify any potential issues.
- Dosing and administration: Amjevita's dosing requirements may differ from Humira, so it's crucial to understand the differences and any necessary adjustments.
- Side effects and allergic reactions: Some patients may experience rare but severe reactions to biosimilars; discuss possible alternatives if you're at high risk.
- Insurance coverage and costs: Verify if Amjevita is covered by your insurance plan and what out-of-pocket expenses you may incur.
- Monitoring and follow-up: After the switch, your doctor will likely need to monitor your condition for any signs of an adverse reaction.
Timeline and Considerations
In the United States, Amjevita's patents won't expire until at least 2036, giving Eli Lilly a significant window of protection. As a result, biosimilar manufacturers like Samsung Bioepis might still face patent infringement claims and restricted availability.
Additional Information
To access Amjevita's savings program, check the manufacturer's website. You can also reach out to the patient support line at 1-877-4-INFO-AI (1-877-446-3624) for additional assistance.
Sources:
[1] Amjevita Prescribing Information. (2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761073s000lbl.pdf
[2] DrugPatentWatch. (2023). United States Patent 10943495. https://www.drugpatentswatch.com/patent/US10943495
[3] DrugPatentWatch. (2023). US Patent 11255591. https://www.drugpatentswatch.com/patent/US11255591